Tamoxifen (TAM), one of the oldest and most frequently utilized SERMs, is now typically prescribed to treat hormone receptor-positive, early-stage breast cancer after surgery to reduce disease recurrence in pre-menopausal women [5,18]. This evidence concerns the gene NR4A1 and breast cancer.